Eli Lily to Acquire Disarm Therapeutics for ~$1.36B
Shots:
- Lilly to acquire Disarm for $135M upfront and ~$1.225B as potential development regulatory and commercial milestones- making a total deal value of ~1.36B
- The acquisition will expand Lilly's R&D efforts in pain and neurodegeneration with the addition of Disarm's preclinical SARM1 programs for axonal degeneration
- Disarm is advancing its potent SARM1 inhibitors in preclinical development intending to deliver patients with peripheral neuropathy and other neurological diseases like ALS and MS
Ref: Eli Lilly | Image: Eli Lilly
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com